Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first two coding-complete genomes provided actionable information in real-time for the deployment of the rVSVΔG-ZEBOV-GP Ebola virus envelope glycoprotein vaccine, available therapeutics, and sequence-based diagnostic assays.
|
31000464 |
2019 |
Hemorrhagic Fever, Ebola
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of Gamma Irradiation on the Antibody Response Measured in Human Serum from Subjects Vaccinated with Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine.
|
31162004 |
2019 |
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ZINC58935541 molecule also showed a strong binding affinity towards the receptor cavity of Ebola virus envelope glycoprotein when simulated for 1.2 ns.
|
30786763 |
2019 |
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EBOV glycoprotein (GP<sub>1,2</sub>) is the sole viral envelope protein and a major component of immunogenicity; it is encoded by the <i>GP</i> gene along with two truncated versions: soluble GP (sGP) and small soluble GP (ssGP). sGP is, in fact, the primary product of the <i>GP</i> gene, and it is secreted in abundance during EBOV infection.
|
31683550 |
2019 |
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the 2013-2016 epidemic in western Africa, caused by Ebola virus (EBOV), illustrated the potential of filovirus outbreaks to escalate to a much larger scale (over 28,000 suspected cases). mAbs against the envelope glycoprotein represent a promising therapeutic platform for managing filovirus infections.
|
29500195 |
2018 |
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structure of the Ebola virus envelope protein MPER/TM domain and its interaction with the fusion loop explains their fusion activity.
|
28874543 |
2017 |
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that the Ebola virus matrix protein, VP40, and envelope glycoprotein, GP, each cooperate with BST2 to induce NF-κB activity, with maximal activity when all three proteins are expressed.
|
28878074 |
2017 |
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to technical difficulty expressing full-length envelope, many structural and functional studies of Ebola envelope protein have been carried out primarily using GP1 lacking its mucin-like domain.
|
28458053 |
2017 |
Hemorrhagic Fever, Ebola
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The vaccine consists of live-attenuated recombinant vesicular stomatitis virus (VSV) and adenovirus serotype-5 (Ad5) expressing Ebola envelope glycoprotein.
|
28152326 |
2017 |
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
We tested the activity of suramin during CHIKV or Ebola virus infection, using CHIKV and Ebola envelope glycoprotein pseudotyped lentiviral vectors and wild-type CHIKV and Ebola virus.
|
27581733 |
2016 |
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
We generated a new live-attenuated vaccine against Ebola virus (EBOV) based on a chimeric virus HPIV3/DeltaF-HN/EboGP that contains the EBOV glycoprotein (GP) as the sole transmembrane envelope protein combined with the internal proteins of human parainfluenza virus type 3 (HPIV3).
|
19010509 |
2009 |
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, the modification of HIV vector tropism by pseudotyping with the envelope glycoprotein from vesicular stomatitis virus (VSV), the Zaire Ebola (EboZ) virus, murine leukemia virus (MuLV), lymphocytic choriomeningitis virus (LCMV), Rabies or the rabies-related Mokola virus encoding LacZ as a reporter gene was evaluated qualitatively and quantitatively in human skin xenografts.
|
17268532 |
2007 |